Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Dosing in Metabolic Syndrome
NCT00272311Phase 4Completed
- Sponsor
- Florida Atlantic University
- Start
- Oct 2006
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aspirin in cardiovascular diseases (CVD) and atherosclerosis (5 arms), sponsored by Florida Atlantic University. Primary endpoint: Change in Nitric Oxide Formation From Baseline at 3 months. Started Oct 2006; status: completed.
02
Drugs
aspirin
03
Conditions
cardiovascular diseases (CVD)atherosclerosis
Beyond the preview
Go deeper on NCT00272311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272311.